STROBE Statement—checklist of items that should be included in reports of observational studies

Section/item	Item No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	page 3 / line 54	Structured Abstract /
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	page 3 / lines 58 to 64	Structured Abstract /
Introduction				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	page 4 / lines 74 to 100	Introduction
Objectives	3	State specific objectives, including any prespecified hypotheses	page 5 / lines 101 to 104	Intrucduction / latest
Methods				
Study design	4	Present key elements of study design early in the paper	page 5 / lines109-117	Methods / Patients and
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	page 5 / lines 109-117	Methods / Patients and design
Participants	6	(a) ***Cohort study***—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up ***Case-control study***—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls ***Cross-sectional study***—Give the eligibility criteria, and the sources and methods of selection of participants	Page 5 / lines 109 to 117	eligibility criteria, and the sources and methods of selection of participants in the "Methods" section, "Patients and design" paragraph
		(b) ***Cohort study***—For matched studies, give matching criteria and number of exposed and unexposed ***Case-control study***—For matched studies, give matching criteria and the number of controls per case	Not matched study	Not matched study
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	page 5 to 7 / lines 120 to 163	Methods / "Data extraction" &
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	page 6 &7 / 127 to 163	sources of data and detailled methods of
Bias	9	Describe any efforts to address potential sources of bias	page 5 / lines 111 to 115 :	Methods / Patients
Study size	10	Explain how the study size was arrived at	no sample size	Methods / Patients
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	page 7 / lines 166 to 174	Methods / Statistical Analysis

Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	page 7 / lines 166 to 174	Methods / Statistical
		(b) Describe any methods used to examine subgroups and interactions	page 7 / lines 171 to 173	Methods / Statistical
		(c) Explain how missing data were addressed	Data not available or lost	Tables 1, 2, 3 & 4
		(d) ***Cohort study***—If applicable, explain how loss to follow-up was addressed ***Case-control study***—If applicable, explain how matching of cases and controls was addressed ***Cross-sectional study***—If applicable, describe analytical methods taking account of sampling strategy	Not applicable in relation with the study design : retrospective analysis with no follow-up or control	Methods / Statistical Analysis
		(e) Describe any sensitivity analyses	No sensitive analysis	No sensitive analysis
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	page 8 / lines 178 to 188	Results / patients
		(b) Give reasons for non-participation at each stage	page 8 / lines 182 to 188	Results / patients
		(c) Consider use of a flow diagram	page 8 / lines 188	see Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	page 8/ line 1180 (reference to Table 1)	see Table 1
		(b) Indicate number of participants with missing data for each variable of interest	when data were not	see Tables 1, 2 & 3
		(c) ***Cohort study***—Summarise follow-up time (eg, average and total amount)	Not a cohort with	Not a cohort with
Outcome data	15*	***Cohort study***—Report numbers of outcome events or summary measures over time	Not a cohort with	Not a cohort with
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	No matched case controls	No matched case controls
		Cross-sectional study—Report numbers of outcome events or summary measures	page 8 to 10 / lines 190 to	Results / "Peak exercise
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	N/A in relation with the objective of the present	N/A in relation with the objective of the present
		(b) Report category boundaries when continuous variables were categorized	page 7 / lines 153to 163 :	Methods / Assessments /
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	No calculation of relative	No calculation of relative
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	page 9 / line 245 to 249 ;	Results / Incremental
Discussion				
Key results	18	Summarise key results with reference to study objectives	page 11 to 13 / line 252 to	Discussion / "Limitation
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	page 15 / lines 366 to 384	Discussion / limitation

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	pages 10-13 / lignes 207 to 307 : The discussion	Discussion
Generalisability	21	Discuss the generalisability (external validity) of the study results	page 14 / lines 321 to 323	Discussion / Limitations
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	page 16 / lines 433-434	Acknowledgements

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article information: http://dx.doi.org/10.21037/jtd-20-1528
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.